Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02016170 · ClinicalTrials.gov registry record · NA
Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor
A NA study, sponsored by University of Florida.
- Completed
- Registry status
- NA
- Development phase
- 82
- Enrollment target
NCT02016170 is a NA study that has completed, run by University of Florida. The registered enrollment target is 82 participants.
The verdict
NCT02016170, a NA study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- NA
- Development phase
- 82 participants
- Enrollment target
Study Summary
Recently, two new oral P2Y12 antagonists have been approved for clinical use: prasugrel, a third generation thienopyridine, and ticagrelor, a first in class cyclopentyltriazolopyrimidine (CPTP). These agents have been shown to be associated with more potent platelet inhibitory effects compared with clopidogrel. In addition, both agents have shown to be superior to clopidogrel in preventing recurrent ischemic events in the setting of acute coronary syndromes (ACS). Understanding how to switch patients from prasugrel to ticagrelor is an unmet need of clinical interest. The proposed PD investigation will have a prospective, randomized, parallel design aimed to show that switching patients from prasugrel to ticagrelor provides similar levels of platelet inhibition.
Interventions
- DRUG Ticagrelor 90mg
- DRUG Ticagrelor 180mg
- DRUG Prasugrel 10mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02016170
The ClinicalTrials.gov registry entry for NCT02016170 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ticagrelor 90mg is the first listed.
NCT02016170 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02016170 about?
NCT02016170 is a clinical study titled "Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor". Recently, two new oral P2Y12 antagonists have been approved for clinical use: prasugrel, a third generation thienopyridine, and ticagrelor, a first in class cyclopentyltriazolopyrimidine (CPTP). These agents have been shown to be associated with more potent platelet inhibitory effects compared with ...
What is the current status of trial NCT02016170?
This trial is currently completed. It is a NA study. The enrollment target is 82 participants. The study started on 2014-03. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02016170?
The interventions under investigation include: Ticagrelor 90mg (DRUG), Ticagrelor 180mg (DRUG), Prasugrel 10mg (DRUG).
Who is sponsoring clinical trial NCT02016170?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.